Legal & General Group PLC Jounce Therapeutics, Inc. Transaction History

Legal & General Group PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.73 - $4.92 $2,440 - $4,398	-894 Reduced 20.24%	3,523 $8,000
Q2 2022 Aug 22, 2022	BUY	$2.8 - $7.67 $5,006 - $13,713	1,788 Added 68.01%	4,417 $13,000
Q2 2021 Aug 12, 2021	BUY	$6.58 - $10.66 $7,297 - $11,821	1,109 Added 72.96%	2,629 $18,000
Q3 2020 Nov 13, 2020	SELL	$4.58 - $10.95 $2,775 - $6,635	-606 Reduced 28.5%	1,520 $12,000
Q1 2020 May 14, 2020	SELL	$2.91 - $8.7 $2,557 - $7,647	-879 Reduced 29.25%	2,126 $10,000
Q1 2019 May 15, 2019	BUY	$3.43 - $6.87 $3,649 - $7,309	1,064 Added 54.82%	3,005 $19,000
Q2 2018 Aug 10, 2018	SELL	$7.27 - $21.88 $3,366 - $10,130	-463 Reduced 19.26%	1,941 $15,000
Q1 2018 May 17, 2018	SELL	$13.4 - $28.4 $12,730 - $26,980	-950 Reduced 28.32%	2,404 $54,000
Q4 2017 Feb 13, 2018	BUY	$12.52 - $17.82 $41,992 - $59,768	3,354	3,354 $43,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.